CRSP Quote, Financials, Valuation and Earnings

Intellia Therapeutics, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of -735.19%. CRISPR Therapeutics AG's return on equity of -26.17% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 55.1%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 149.52%. Given that Intellia Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Intellia Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.

CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.054, suggesting its more volatile than the S&P 500 by 105.378%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. CRISPR Therapeutics AG's net income of -$106.4M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 119.61x versus 16.38x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 28.26%. CRISPR Therapeutics AG's return on equity of -26.17% beat Novartis AG's return on equity of 33.87%.

CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 55.1%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could fall by -2.17%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.422%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.9% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Novartis AG quarterly revenues of $13.9B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Novartis AG's net income of $3.9B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 119.61x versus 4.99x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 8.84%. CRISPR Therapeutics AG's return on equity of -26.17% beat BeOne Medicines Ltd.'s return on equity of 1.92%.

CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 55.1%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 31.68%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines Ltd., analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines Ltd..

CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.26%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. CRISPR Therapeutics AG's net income of -$106.4M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 584.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 119.61x versus 6.79x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 34.76%. CRISPR Therapeutics AG's return on equity of -26.17% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 55.1%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 8.51%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals, Inc..

CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 119.61x versus 10.01x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.